- Report
- January 2024
- 200 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1439EUR$1,500USD£1,240GBP
- Report
- May 2024
- 184 Pages
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- February 2022
- 220 Pages
Global
From €9115EUR$9,500USD£7,851GBP
- Report
- May 2020
- 200 Pages
Global
From €6668EUR$6,950USD£5,744GBP
- Report
- March 2024
- 77 Pages
Global
From €3500EUR$3,908USD£3,120GBP
- Report
- March 2022
Global
From €4654EUR$4,850USD£4,008GBP
- Report
- March 2021
Japan, United States, ... Japan, United States, Europe
From €912EUR$950USD£785GBP
- Report
- February 2020
Japan, United States, ... Japan, United States, Europe
From €912EUR$950USD£785GBP
- Report
- May 2024
- 50 Pages
Global
From €2543EUR$2,650USD£2,190GBP
- Book
- January 2010
- 616 Pages
- Book
- October 2010
- 408 Pages
Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation. It is also used to control ventricular rate in supraventricular tachycardia. Digoxin is a part of the cardiovascular drug market, which includes drugs used to treat heart failure, hypertension, and other cardiovascular diseases. Digoxin is used to treat heart failure by increasing the force of contraction of the heart muscle, which helps the heart pump more efficiently. It is also used to treat atrial fibrillation by slowing the ventricular rate and helping to maintain normal sinus rhythm.
Digoxin is available in both oral and injectable forms. It is available as a generic drug and is also sold under the brand names Lanoxin and Digitek. Digoxin is available in a variety of strengths and formulations, including tablets, capsules, and injectable solutions.
Companies in the Digoxin market include GlaxoSmithKline, Pfizer, Sanofi, Mylan, and Teva Pharmaceuticals. Show Less Read more
